New hope for duchenne: targeted drug trial aims to slow muscle decline
NCT ID NCT07587242
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests an experimental drug called AOC 1044 (delpacibart zotadirsen) in 70 boys aged 7 to 16 with Duchenne muscular dystrophy who have a specific genetic change (exon 44 skipping). The drug is given through a vein and aims to improve muscle function, such as how fast they can stand up from a chair. Half the participants will receive the drug and half a placebo, and all will be followed for over a year to check safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMUSCULAR DISEASES (NMD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.